UA91027C2 - ИНГИБИТОРЫ ВЗАИМОДЕЙСТВИЯ МЕЖДУ MDM2 И р53 - Google Patents

ИНГИБИТОРЫ ВЗАИМОДЕЙСТВИЯ МЕЖДУ MDM2 И р53

Info

Publication number: UA91027C2
Authority: UA; Ukraine
Prior art keywords: mdm2; interaction; inhibitors; formula; compounds
Prior art date: 2004-09-22

Application number

UAA200702657A

Other languages

English (en)

Ukrainian (uk)

Inventor

Жан Фернан Арман Лакрамп

Кристоф Мэйер

Янник Эме Эдди Лигни

Имре Кристиан Франсис Чока

Хийфте Люк ван

Жанин Артс

Бруно Шентьес

Камилл Жорж Вермут

Бруно Гетлен

Жан-Мари Контрерас

Мурель Жубер

Original Assignee

Янссен Фармацевтика Н.В.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-09-22

Filing date

2005-09-16

Publication date

2010-06-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34928531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA91027(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-09-16 Application filed by Янссен Фармацевтика Н.В. filed Critical Янссен Фармацевтика Н.В.

2010-06-25 Publication of UA91027C2 publication Critical patent/UA91027C2/ru

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

UAA200702657A 2004-09-22 2005-09-16 ИНГИБИТОРЫ ВЗАИМОДЕЙСТВИЯ МЕЖДУ MDM2 И р53 UA91027C2 (ru)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP04077630		2004-09-22

Publications (1)

Publication Number	Publication Date
UA91027C2 true UA91027C2 (ru)	2010-06-25

Family

ID=34928531

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200702657A UA91027C2 (ru)	2004-09-22	2005-09-16	ИНГИБИТОРЫ ВЗАИМОДЕЙСТВИЯ МЕЖДУ MDM2 И р53

Country Status (29)

Country	Link
US (2)	US7834016B2 (ru)
EP (1)	EP1809622B1 (ru)
JP (1)	JP5156378B2 (ru)
KR (1)	KR101331786B1 (ru)
CN (1)	CN101023074B (ru)
AP (1)	AP2446A (ru)
AR (1)	AR053412A1 (ru)
AT (1)	ATE474833T1 (ru)
AU (1)	AU2005286525B2 (ru)
BR (1)	BRPI0515594B8 (ru)
CA (1)	CA2579915C (ru)
CR (1)	CR9081A (ru)
DE (1)	DE602005022472D1 (ru)
DK (1)	DK1809622T3 (ru)
EA (1)	EA012452B1 (ru)
EC (1)	ECSP077335A (ru)
ES (1)	ES2349358T3 (ru)
HR (1)	HRP20100561T1 (ru)
IL (1)	IL182009A (ru)
MX (1)	MX2007003375A (ru)
MY (1)	MY136800A (ru)
NO (1)	NO341281B1 (ru)
NZ (1)	NZ553646A (ru)
SG (1)	SG155941A1 (ru)
SI (1)	SI1809622T1 (ru)
TW (1)	TWI372758B (ru)
UA (1)	UA91027C2 (ru)
WO (1)	WO2006032631A1 (ru)
ZA (1)	ZA200702341B (ru)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2608116A1 (en)	2005-05-10	2006-11-16	Intermune, Inc.	Method of modulating stress-activated protein kinase system
US8921376B2 (en)	2005-05-20	2014-12-30	Vertex Pharmaceuticals Incorporated	Pyrrolopyridines useful as inhibitors of protein kinase
US8232298B2 (en)	2006-03-22	2012-07-31	Janssen Pharmaceutica N.V.	Inhibitors of the interaction between MDM2 and P53
DE602007007065D1 (de) *	2006-03-22	2010-07-22	Janssen Pharmaceutica Nv	Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53
US7875636B2 (en) *	2006-04-12	2011-01-25	Merck Sharp & Dohme Corp.	Pyridyl amide T-type calcium channel antagonists
US8138205B2 (en)	2006-07-07	2012-03-20	Kalypsys, Inc.	Heteroarylalkoxy-substituted quinolone inhibitors of PDE4
WO2008006050A2 (en)	2006-07-07	2008-01-10	Govek Steven P	Bicyclic heteroaryl inhibitors of pde4
US7622495B2 (en) *	2006-10-03	2009-11-24	Neurim Pharmaceuticals (1991) Ltd.	Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
WO2008121442A2 (en) *	2007-02-09	2008-10-09	The Uab Research Foundation	Pa28-gamma regulation in cells
US20100129933A1 (en) *	2007-04-26	2010-05-27	Forschungszentrum Karlsruhe Gmbh	Method for detecting the binding between mdm2 and the proteasome
PA8792401A1 (es) *	2007-08-06	2009-03-31	Janssen Pharmaceutica Nv	Fenilendiaminas
US8288377B2 (en)	2007-09-21	2012-10-16	Janssen Pharmaceutica N.V.	Inhibitors of the interaction between MDM2 and p53
JO2704B1 (en) *	2007-09-21	2013-03-03	جانسين فارماسوتيكا ان في	Interference inhibition factors between MD2 and B53
CA2701594C (en) *	2007-10-24	2014-02-18	Merck Sharp & Dohme Corp.	Heterocycle phenyl amide t-type calcium channel antagonists
WO2009073713A1 (en) *	2007-12-05	2009-06-11	Enanta Pharmaceuticals, Inc.	Oximyl macrocyclic derivatives
WO2009073780A1 (en) *	2007-12-06	2009-06-11	Enanta Pharmaceuticals, Inc.	Process for making macrocyclic oximyl hepatitis c protease inhibitors
CA3034994A1 (en)	2008-06-03	2009-12-10	Intermune, Inc.	Substituted aryl-2 pyridone compounds and use thereof for treating inflammatory and fibrotic disorders
MY152018A (en) *	2009-02-04	2014-08-15	Janssen Pharmaceutica Nv	Indole derivatives as anticancer agents
US20120135089A1 (en) *	2009-03-17	2012-05-31	Stockwell Brent R	E3 ligase inhibitors
EP2311823A1 (en)	2009-10-15	2011-04-20	AC Immune S.A.	2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
EP2499145B1 (en)	2009-11-12	2016-01-27	The Regents Of The University Of Michigan	Spiro-oxindole mdm2 antagonists
CA2785716A1 (en)	2009-12-30	2011-07-07	Arqule, Inc.	Substituted pyrrolo-aminopyrimidine compounds
CN103153958A (zh) *	2010-07-02	2013-06-12	先正达参股股份有限公司	新颖的杀微生物的二肟醚衍生物
FR2967072B1 (fr)	2010-11-05	2013-03-29	Univ Dundee	Procede pour ameliorer la production de virus et semences vaccinales influenza
UY33725A (es)	2010-11-12	2012-06-29	Sanofi Sa	Antagonistas de mdm2 de espiro-oxindol
CN103717605B (zh)	2011-05-11	2016-05-18	密执安州立大学董事会	螺-羟吲哚mdm2拮抗剂
US8815926B2 (en) *	2012-01-26	2014-08-26	Novartis Ag	Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
AR092742A1 (es)	2012-10-02	2015-04-29	Intermune Inc	Piridinonas antifibroticas
RU2509808C1 (ru) *	2012-10-30	2014-03-20	Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН)	СПОСОБ ОПРЕДЕЛЕНИЯ ЧУВСТВИТЕЛЬНОСТИ КЛЕТОК НЕМЕЛКОКЛЕТОЧНОГО РАКА ЛЕГКИХ К ДЕЙСТВИЮ ПРЕПАРАТОВ, РЕАКТИВИРУЮЩИХ БЕЛОК р53
KR20140059002A (ko) *	2012-11-07	2014-05-15	한국과학기술원	다제내성 종양 치료를 위한 항암제 및 치료방법
KR102196882B1 (ko)	2012-12-20	2020-12-30	머크 샤프 앤드 돔 코포레이션	Hdm2 억제제로서의 치환된 이미다조피리딘
SG11201606080SA (en)	2014-02-03	2016-08-30	Vitae Pharmaceuticals Inc	Dihydropyrrolopyridine inhibitors of ror-gamma
CA2943363A1 (en)	2014-04-02	2015-10-08	Intermune, Inc.	Anti-fibrotic pyridinones
CN107074852B (zh)	2014-10-14	2019-08-16	生命医药有限责任公司	ROR-γ的二氢吡咯并吡啶抑制剂
US9845308B2 (en)	2014-11-05	2017-12-19	Vitae Pharmaceuticals, Inc.	Isoindoline inhibitors of ROR-gamma
US9663515B2 (en)	2014-11-05	2017-05-30	Vitae Pharmaceuticals, Inc.	Dihydropyrrolopyridine inhibitors of ROR-gamma
TW201702218A (zh)	2014-12-12	2017-01-16	美國杰克森實驗室	關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
CA2976752C (en)	2015-02-20	2019-12-17	Daiichi Sankyo Company, Limited	Method for treating cancer by combined use
BR122019027518B8 (pt) *	2015-05-11	2021-04-13	Basf Se	processos para a preparação de um composto, composto de amina de dicloropiridazina e mistura do composto de amina de dicloropiridazina
WO2016180833A1 (en)	2015-05-11	2016-11-17	Basf Se	Process for preparing 4-amino-pyridazines
US10301261B2 (en)	2015-08-05	2019-05-28	Vitae Pharmaceuticals, Llc	Substituted indoles as modulators of ROR-gamma
EP3331895B1 (en)	2015-08-06	2020-07-29	Chimerix, Inc.	Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents
EP3377482B1 (en)	2015-11-20	2021-05-12	Vitae Pharmaceuticals, LLC	Modulators of ror-gamma
US9630968B1 (en)	2015-12-23	2017-04-25	Arqule, Inc.	Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
TWI757266B (zh)	2016-01-29	2022-03-11	美商維它藥物有限責任公司	ＲＯＲ－γ調節劑
JP7001614B2 (ja)	2016-04-06	2022-02-03	ザリージェンツオブザユニヴァシティオブミシガン	リガンド依存性の標的タンパク質分解のための単官能性中間体
JP7037500B2 (ja)	2016-04-06	2022-03-16	ザリージェンツオブザユニヴァシティオブミシガン	Ｍｄｍ２タンパク質分解剤
ES2858151T3 (es)	2016-05-20	2021-09-29	Hoffmann La Roche	Conjugados de PROTAC-anticuerpo y procedimientos de uso
US9481674B1 (en)	2016-06-10	2016-11-01	Vitae Pharmaceuticals, Inc.	Dihydropyrrolopyridine inhibitors of ROR-gamma
TW201811795A (zh)	2016-08-24	2018-04-01	美商亞闊股份有限公司	胺基－吡咯并嘧啶酮化合物及其用途
HRP20211462T1 (hr)	2017-04-24	2021-12-24	Aurigene Discovery Technologies Limited	Postupci uporabe za trisupstituirane derivate benzotriazola kao inhibitora dihidroorotatne oksigenaze
WO2019018975A1 (en)	2017-07-24	2019-01-31	Vitae Pharmaceuticals, Inc.	INHIBITORS OF ROR GAMMA
MA49685A (fr)	2017-07-24	2021-04-14	Vitae Pharmaceuticals Llc	INHIBITEURS DE ROR gamma
WO2019060692A1 (en)	2017-09-21	2019-03-28	Chimerix, Inc.	MORPHIC FORMS OF 4-AMINO-7- (3,4-DIHYDROXY-5- (HYDROXYMETHYL) -ETRAHYDROFURAN-2-YL) -2-METHYL-7H-PYRROLO [2,3-D] PYRIMIDINE-5-CARBOXAMIDE AND THEIR USES
CN108409839B (zh) *	2018-02-13	2020-08-11	中国人民解放军军事科学院军事医学研究院	一种MDM2与p53相互作用的多肽抑制剂及其应用
ES3038736T3 (en) *	2018-02-20	2025-10-14	Servier Lab	Benzotriazole derivative for use in treating double and triple hit diffuse large b cell lymphoma
BR112022015379A2 (pt)	2020-02-04	2022-09-27	Mindset Pharma Inc	Derivados de 3-pirrolidino-indol como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc
TR202002325A2 (tr) *	2020-02-17	2021-08-23	Bahcesehir Ueniversitesi	Yeni̇ mouse double minute 2 (mdm2) i̇nhi̇bi̇törü olarak kullanmak i̇çi̇n drg-mdm2-4
CN113293046B (zh) *	2021-05-26	2021-11-30	安徽博洋润滑科技有限公司	一种低发尘润滑脂及其制备方法
WO2023056069A1 (en)	2021-09-30	2023-04-06	Angiex, Inc.	Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en)	2023-05-23	2024-11-28	Valerio Therapeutics	Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9201755D0 (en)	1992-01-28	1992-03-11	British Bio Technology	Compounds
AUPO863197A0 (en)	1997-08-18	1997-09-11	Fujisawa Pharmaceutical Co., Ltd.	Novel derivatives
US6861448B2 (en) *	1998-01-14	2005-03-01	Virtual Drug Development, Inc.	NAD synthetase inhibitors and uses thereof
US6309492B1 (en)	1998-09-16	2001-10-30	Marc A. Seidner	Polymer fill coating for laminate or composite wood products and method of making same
UA71587C2 (ru)	1998-11-10	2004-12-15	Шерінг Акцієнгезелльшафт	Translated By PlajАМИДЫ АНТРАНИЛОВОЙ КИСЛОТЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕЧЕБНЫХ СРЕДСТВ
GB9824579D0 (en) *	1998-11-10	1999-01-06	Novartis Ag	Organic compounds
PL350998A1 (en) *	1999-03-24	2003-02-24	Anormed Inc	Chemokine recpetor binding heterocyclic compounds
AU1734401A (en) *	1999-12-09	2001-06-18	Mitsubishi Pharma Corporation	Carboxyamido derivatives
JP2004508421A (ja)	2000-09-15	2004-03-18	アノーメッド　インコーポレイティド	ケモカインレセプター結合性ヘテロ環式化合物
ES2566056T3 (es)	2001-03-29	2016-04-08	Eli Lilly And Company	N-(2-ariletil)bencilaminas como antagonistas del receptor 5-HT6
AU2002357728A1 (en) *	2001-11-09	2003-05-19	The Regents Of The University Of California	Alpha-helix mimicry by a class of organic molecules
PL370176A1 (en)	2001-11-13	2005-05-16	3-Dimensional Pharmaceuticals, Inc.	Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
ES2301717T3 (es)	2001-12-18	2008-07-01	F. Hoffmann-La Roche Ag	Cis-2,4,5-trifenil-imidazolinas y su utilizacion para el tratamiento de tumores.
GB0215650D0 (en)	2002-07-05	2002-08-14	Cyclacel Ltd	Bisarylsufonamide compounds
GB0428187D0 (en)	2004-12-23	2005-01-26	Univ Liverpool	Cancer treatment
EP1844048B1 (en) *	2005-01-14	2010-05-26	Janssen Pharmaceutica N.V.	Pyrazolopyrimidines as cell cycle kinase inhibitors
WO2007115289A2 (en)	2006-04-05	2007-10-11	Novartis Ag	Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer

2005
- 2005-09-16 JP JP2007532886A patent/JP5156378B2/ja not_active Expired - Fee Related
- 2005-09-16 WO PCT/EP2005/054604 patent/WO2006032631A1/en not_active Ceased
- 2005-09-16 KR KR1020077008663A patent/KR101331786B1/ko not_active Expired - Fee Related
- 2005-09-16 EP EP05786991A patent/EP1809622B1/en not_active Expired - Lifetime
- 2005-09-16 BR BRPI0515594A patent/BRPI0515594B8/pt not_active IP Right Cessation
- 2005-09-16 AP AP2007003947A patent/AP2446A/xx active
- 2005-09-16 CN CN2005800317557A patent/CN101023074B/zh not_active Expired - Fee Related
- 2005-09-16 SI SI200531127T patent/SI1809622T1/sl unknown
- 2005-09-16 SG SG200906267-0A patent/SG155941A1/en unknown
- 2005-09-16 US US11/575,552 patent/US7834016B2/en not_active Expired - Fee Related
- 2005-09-16 UA UAA200702657A patent/UA91027C2/ru unknown
- 2005-09-16 EA EA200700699A patent/EA012452B1/ru not_active IP Right Cessation
- 2005-09-16 NZ NZ553646A patent/NZ553646A/en not_active IP Right Cessation
- 2005-09-16 AU AU2005286525A patent/AU2005286525B2/en not_active Ceased
- 2005-09-16 ES ES05786991T patent/ES2349358T3/es not_active Expired - Lifetime
- 2005-09-16 MX MX2007003375A patent/MX2007003375A/es active IP Right Grant
- 2005-09-16 HR HR20100561T patent/HRP20100561T1/hr unknown
- 2005-09-16 DE DE602005022472T patent/DE602005022472D1/de not_active Expired - Lifetime
- 2005-09-16 DK DK05786991.9T patent/DK1809622T3/da active
- 2005-09-16 CA CA2579915A patent/CA2579915C/en not_active Expired - Fee Related
- 2005-09-16 AT AT05786991T patent/ATE474833T1/de not_active IP Right Cessation
- 2005-09-21 TW TW094132574A patent/TWI372758B/zh not_active IP Right Cessation
- 2005-09-21 AR ARP050103960A patent/AR053412A1/es not_active Application Discontinuation
- 2005-09-22 MY MYPI20054466A patent/MY136800A/en unknown
2007
- 2007-03-19 IL IL182009A patent/IL182009A/en active IP Right Grant
- 2007-03-20 ZA ZA200702341A patent/ZA200702341B/xx unknown
- 2007-03-22 EC EC2007007335A patent/ECSP077335A/es unknown
- 2007-04-20 CR CR9081A patent/CR9081A/es not_active Application Discontinuation
- 2007-04-23 NO NO20072058A patent/NO341281B1/no not_active IP Right Cessation
2010
- 2010-11-03 US US12/938,633 patent/US8404683B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ES2349358T3 (es)	2010-12-30
BRPI0515594B1 (pt)	2020-09-24
NZ553646A (en)	2010-07-30
ATE474833T1 (de)	2010-08-15
CA2579915A1 (en)	2006-03-30
US8404683B2 (en)	2013-03-26
CR9081A (es)	2008-11-24
KR20070058622A (ko)	2007-06-08
HK1107651A1 (en)	2008-04-11
SI1809622T1 (sl)	2010-11-30
CN101023074B (zh)	2012-10-10
US20080039472A1 (en)	2008-02-14
US20110053937A1 (en)	2011-03-03
TWI372758B (en)	2012-09-21
NO341281B1 (no)	2017-10-02
SG155941A1 (en)	2009-10-29
AR053412A1 (es)	2007-05-09
NO20072058L (no)	2007-04-23
US7834016B2 (en)	2010-11-16
ECSP077335A (es)	2007-04-26
EA012452B1 (ru)	2009-10-30
HRP20100561T1 (hr)	2010-11-30
WO2006032631A1 (en)	2006-03-30
CA2579915C (en)	2010-06-22
JP5156378B2 (ja)	2013-03-06
ZA200702341B (en)	2010-09-29
MX2007003375A (es)	2007-05-07
BRPI0515594B8 (pt)	2021-05-25
TW200626579A (en)	2006-08-01
EA200700699A1 (ru)	2007-08-31
MY136800A (en)	2008-11-28
KR101331786B1 (ko)	2013-11-21
AU2005286525B2 (en)	2011-06-16
JP2008513532A (ja)	2008-05-01
CN101023074A (zh)	2007-08-22
AP2446A (en)	2012-08-31
IL182009A0 (en)	2007-07-24
EP1809622A1 (en)	2007-07-25
BRPI0515594A (pt)	2008-07-29
DE602005022472D1 (de)	2010-09-02
EP1809622B1 (en)	2010-07-21
DK1809622T3 (da)	2010-11-08
AU2005286525A1 (en)	2006-03-30
AP2007003947A0 (en)	2007-04-30
IL182009A (en)	2012-06-28

Publication	Publication Date	Title
UA91027C2 (ru)	2010-06-25	ИНГИБИТОРЫ ВЗАИМОДЕЙСТВИЯ МЕЖДУ MDM2 И р53
TW200610531A (en)	2006-04-01	Phthalazine derivatives as PARP inhibitors
MX2010003060A (es)	2010-04-07	Inhibidores de la interaccion entre mdm2 y p53.
ATE547415T1 (de)	2012-03-15	Inhibitoren der wechselwirkung zwischen mdm2 und p53
UA91002C2 (ru)	2010-06-25	7-фенилалкилзамещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поле(адф-рибоза)полимеразы
MY169515A (en)	2019-04-19	Quinazolinedione derivatives as parp inhibitors
IL185275A0 (en)	2008-02-09	N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
ATE470665T1 (de)	2010-06-15	Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53
SG154434A1 (en)	2009-08-28	Quinazolinone derivatives as parp inhibitors
UA91007C2 (ru)	2010-06-25	Замещенные 6-циклогексилалкилом замещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли-(адф-рибоза)полимеразы
SE0302811D0 (sv)	2003-10-23	Novel compounds
ATE433447T1 (de)	2009-06-15	Pyrimiidinverbindungen
IL181271A0 (en)	2007-07-04	Triazolophthalazine derivatives and pharmaceutical compositions containing the same
MXPA05001354A (es)	2005-04-28	Piperidina-ftalazonas sustituidas por pirrolidinodiona como inhibidores pde4.
UA89618C2 (ru)	2010-02-25	6-замещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли(адф-рибоза)полимеразы
WO2003059898A3 (en)	2004-02-26	Eponemycin and epoxomicin analogs and uses thereof
TNSN08191A1 (en)	2009-10-30	Kinase inhibitors
TW200745084A (en)	2007-12-16	Novel compounds
PT2049480E (pt)	2013-12-16	Derivados de 2-arilindole como inibidores da mpges-i
TW200604197A (en)	2006-02-01	New compounds
IL173810A0 (en)	2006-07-05	Imidazopyridine derivatives and pharmaceutical compositions containing the same
IL173809A0 (en)	2006-07-05	Imidazopyridine derivatives and pharmaceutical compositions containing the same
IL173895A0 (en)	2006-07-05	Imidazopyridine derivatives and pharmaceutical compositions containing the same
TW200624429A (en)	2006-07-16	Novel cysteine protease inhibitors